Publications by authors named "S Geha"

Neurofibromatosis Type I (NF1) is a rare genetic disorder. NF1 patients frequently develop a benign tumor in peripheral nerve plexuses called plexiform neurofibroma. In the past two decades, tissue-specific Nf1 knockout mouse models were developed using commercially available tissue-specific Cre recombinase and the Nf1 flox mice to mimic neurofibroma development.

View Article and Find Full Text PDF

Animal models represent the workhorse of the neuroscience field. Despite this, today, there is still no step-by-step protocol to dissect a complete rodent nervous system, nor is there a complete schematic representing it that is freely available. Only methods to harvest the brain, the spinal cord, a specific dorsal root ganglion, and the sciatic nerve (separately) are available.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the therapeutic potential of copper-64 (Cu)-DOTHA-PSMA for treating prostate cancer, building on previous findings related to its use in PET imaging.
  • LNCaP tumor-bearing mice were treated with Cu-DOTHA-PSMA, and results showed that this treatment led to longer survival compared to both a control group and lutetium-177 (Lu)-PSMA-617, while maintaining normal red blood cell levels and showing minimal radiation injury.
  • Overall, Cu-DOTHA-PSMA was indicated to be an effective treatment option with manageable toxicity, although there are concerns about radiation exposure to the liver and gastrointestinal tract.
View Article and Find Full Text PDF

The elevated expression of the splicing regulator SRSF10 in metastatic colorectal cancer (CRC) stimulates the production of the pro-tumorigenic splice variant. We discovered a group of small molecules with an aminothiazole carboxamide core (GPS167, GPS192 and others) that decrease production of . While additional alternative splicing events regulated by SRSF10 are affected by GPS167/192 in HCT116 cells (e.

View Article and Find Full Text PDF
Article Synopsis
  • The study looked at removing gallbladders that weren’t cancerous to see if there were hidden cancers or serious changes in the cells.
  • Researchers tried a special method to check if it could find hidden gallbladder cancer and serious cell changes using data from many past operations.
  • They found that certain factors like age and the surgery type helped identify cancer, but for the serious cell changes, more detailed checks were needed.
View Article and Find Full Text PDF